UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): January 4, 2018
| SECOND SIGHT MEDICAL PRODUCTS, INC. | |||||
| (Exact Name of Registrant as Specified in Its Charter) | |||||
| California | |||||
| (State or Other Jurisdiction of Incorporation) | |||||
| 333-198073 | 02-0692322 | ||||
| (Commission File Number) | (IRS Employer Identification No.) | ||||
|
12744 San Fernando Road, Suite 400 |
|||||
| (Address of Principal Executive Offices) | |||||
| (818) 833-5000 | |||||
| (Registrant's Telephone Number, Including Area Code) | |||||
| (Former Name or Former Address, if Changed Since Last Report) | |||||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
ITEM 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On January 4, 2018, the Board of Directors of Second Sight Medical Products, Inc. (the “Company”) granted options to certain of its officers and other executives pursuant to the Second Sight Medical Products, Inc. 2011 Equity Incentive Plan as follows:
| Name | Title | Amount |
| Will McGuire | President and Chief Executive Officer | 450,000 |
| Robert Greenberg, M.D., Ph.D. | Chairman | 140,000 |
| Steve Okland | Commercial Vice President, U.S. and Canada | 140,000 |
| Ted Randolph | Vice President of Manufacturing | 45,000 |
| Greg Cosendai | Vice President Clinical Affairs | 65,000 |
| Amit Kukreja | Vice President Global Reimbursement & Market Access | 65,000 |
| David Jacques | Vice President – Research & Development | 125,000 |
| Frank Vandeputte | Vice President and General Manager, EMEA | 30,000 |
The options have a strike price of $2.06 per share, which was the closing price of Company’s shares as reported by Nasdaq on the date of grant, January 4, 2018. The options have a 10-year term, and vest 25% on the one year anniversary of the grant date and 6.25% each calendar quarter thereafter until fully vested, with the validity of the options hinging on continued employment with the Company.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: January 8, 2018
SECOND SIGHT MEDICAL PRODUCTS, INC.
/s/ Thomas B. Miller
By: Thomas B. Miller
Chief Financial Officer